Track record · closed signal

Aurinia Pharmaceuticals Inc (AUPH) — closed signal from March 23, 2026

Near target Published before the outcome was known, scored automatically when the window closed on June 21, 2026 — +11.1% at the close.

Predicted vs. what happened

AUPH price · publication thesis → realized outcomesplit-adjusted

$14.20 – $15.10Entry zone — fair-value band

$14.82Published — price the day we called it

$17.04Target — the price the thesis aimed for

$16.88Peak — highest point inside the window, not a realized return

$16.46Window close — end-of-window price, context only

What happened

Near target

Came within reach: 93% of the predicted growth at its peak, just short of the target.

At window close

+11.1%

realized, from the publication price to the last close inside the window

Peak gain

+13.9%

peak, from the publication price — not a realized return

S&P 500, same window

+14.2%

SPY over the identical days, dividend-adjusted

Window close

$16.46

last close inside the window, ended June 21, 2026

Peak price

$16.88

peak on April 23, 2026 — not a realized return

Days to target

—

The thesis — published March 23, 2026

Predicted growth

+15%

over the measurement window

Target price

$17.04

the price the thesis aimed for

Entry zone

$14.20 – $15.10

the fair-value band we waited for

Price at publication

$14.82

published March 23, 2026

Confidence

78%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Aurinia stands out because it is showing real sales strength, has plenty of cash, and more committed owners rather than hopes of a takeover. Recent media and investor activity could help lift the stock if the company keeps delivering results. The short-term technical picture isn't fully confirmed, so this is not a fast-chase idea, but the valuation limits how far the share price might fall versus peers.

Primary drivers

Lupkynis is driving steady sales and commercial progress
Large cash holdings lower risk of emergency financing
Active investors and insiders raise chances of a rerating
Shares trade cheaply versus some profitable biotech names

How it played out

AUPH: rose 13.9% but missed the target

Lyra published AUPH at $14.82 with expected growth of 15% and a $17.04 target. The thesis pointed to steady Lupkynis sales, large cash holdings, committed owners and insiders, and a low valuation relative to some profitable biotech companies.

The shares reached a peak of $16.88 on April 23, 2026, a gain of 13.9%. That peak stayed below the target, so the target was never reached during the window. AUPH ended the window at $16.46 on June 21, 2026. The price rose and came close, but the published thesis only partially played out.

What happened during the window

On March 30, 2026, Aurinia announced an agreement to acquire Kezar Life Sciences. On May 7, 2026, Aurinia reported first-quarter total revenue of $77.7 million and Lupkynis net product sales of $73.6 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All AUPH signals